Intestinal microbiota in health and disease: role of bifidobacteria in gut homeostasis.
The pool of microbes inhabiting our body is known as "microbiota" and their collective genomes as "microbiome". The colon is the most densely populated organ in the human body, although other parts, such as the skin, vaginal mucosa, or respiratory tract, also harbour specific microbiota. This microbial community regulates some important metabolic and physiological functions of the host, and drives the maturation of the immune system in early life, contributing to its homeostasis during life. Alterations of the intestinal microbiota can occur by changes in composition (dysbiosis), function, or microbiota-host interactions and they can be directly correlated with several diseases. The only disease in which a clear causal role of a dysbiotic microbiota has been demonstrated is the case of Clostridium difficile infections. Nonetheless, alterations in composition and function of the microbiota have been associated with several gastrointestinal diseases (inflammatory bowel disease, colorectal cancer, or irritable bowel syndrome), as well as extra-intestinal pathologies, such as those affecting the liver, or the respiratory tract (e.g., allergy, bronchial asthma, and cystic fibrosis), among others. Species of Bifidobacterium genus are the normal inhabitants of a healthy human gut and alterations in number and composition of their populations is one of the most frequent features present in these diseases. The use of probiotics, including bifidobacteria strains, in preventive medicine to maintain a healthy intestinal function is well documented. Probiotics are also proposed as therapeutic agents for gastrointestinal disorders and other pathologies. The World Gastroenterology Organization recently published potential clinical applications for several probiotic formulations, in which species of lactobacilli are predominant. This review is focused on probiotic preparations containing Bifidobacterium strains, alone or in combination with other bacteria, which have been tested in human clinical studies. In spite of extensive literature on and research into this topic, the degree of scientific evidence of the effectiveness of probiotics is still insufficient in most cases. More effort need to be made to design and conduct accurate human studies demonstrating the efficacy of probiotics in the prevention, alleviation, or treatment of different pathologies.
Rafael Tojo, Gastroenterology Department, Hospital de Cabueñes, 33203 Gijón, Asturias, Spain.
Rafael
R
Tojo
Rafael Tojo, Gastroenterology Department, Hospital de Cabueñes, 33203 Gijón, Asturias, Spain.
Adolfo
A
Suárez
Rafael Tojo, Gastroenterology Department, Hospital de Cabueñes, 33203 Gijón, Asturias, Spain.
Marta G
MG
Clemente
Rafael Tojo, Gastroenterology Department, Hospital de Cabueñes, 33203 Gijón, Asturias, Spain.
Clara G
CG
de los Reyes-Gavilán
Rafael Tojo, Gastroenterology Department, Hospital de Cabueñes, 33203 Gijón, Asturias, Spain.
Abelardo
A
Margolles
Rafael Tojo, Gastroenterology Department, Hospital de Cabueñes, 33203 Gijón, Asturias, Spain.
Miguel
M
Gueimonde
Rafael Tojo, Gastroenterology Department, Hospital de Cabueñes, 33203 Gijón, Asturias, Spain.
Patricia
P
Ruas-Madiedo
D064806:Dysbiosis; D006304:Health Status; D006706:Homeostasis; D054884:Host-Pathogen Interactions; D006801:Humans; D007410:Intestinal Diseases / Q000382:microbiology* / Q000628:therapy; D007422:Intestines / Q000382:microbiology*; D008107:Liver Diseases / Q000382:microbiology; D008171:Lung Diseases / Q000382:microbiology; D064307:Microbiota; D019936:Probiotics / Q000627:therapeutic use; D012307:Risk Factors
Bifidobacterium; Colorectal cancer; Dysbiosis; Functional foods; Inflammatory bowel disease; Intestinal microbiota; Irritable bowel syndrome; Liver disease; Probiotics; Respiratory disease